Replies to post #245556 on Biotech Values

[swampboots]

APLS ($61) Syfovre: A ruthless irreversible loss of desperately prized eye real estate with no feasible current solution may allow for a beset mass of many , no rational lifting of a finger to reject an FDA approved protocol.

[DewDiligence]

APLS raising $345M* cash on unspecified terms:

https://finance.yahoo.com/news/apellis-pharmaceuticals-announces-proposed-public-122200331.html

Caveat emptor. I’m skeptical about the commercial uptake of Syfovre.

*Assuming exercise of underwriter’s option.